PDS Biotechnology (NASDAQ:PDSB) Stock Rating Lowered by Wall Street Zen

PDS Biotechnology (NASDAQ:PDSB) was downgraded by Wall Street Zen from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Saturday.

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $13.00 target price on shares of PDS Biotechnology in a report on Wednesday.

PDS Biotechnology Price Performance

NASDAQ PDSB opened at $1.75 on Friday. The business’s fifty day moving average price is $1.34 and its 200-day moving average price is $1.47. The stock has a market capitalization of $79.99 million, a price-to-earnings ratio of -1.51 and a beta of 1.27. The company has a debt-to-equity ratio of 0.55, a current ratio of 2.84 and a quick ratio of 2.84. PDS Biotechnology has a 1-year low of $0.85 and a 1-year high of $4.42.

PDS Biotechnology (NASDAQ:PDSB) last announced its earnings results on Wednesday, May 14th. The company reported ($0.21) EPS for the quarter, topping analysts’ consensus estimates of ($0.25) by $0.04. On average, equities analysts predict that PDS Biotechnology will post -1.2 earnings per share for the current year.

Institutional Investors Weigh In On PDS Biotechnology

A number of institutional investors and hedge funds have recently bought and sold shares of PDSB. Raymond James Financial Inc. bought a new stake in PDS Biotechnology during the fourth quarter valued at about $26,000. Virtu Financial LLC bought a new stake in PDS Biotechnology during the fourth quarter valued at about $89,000. Blair William & Co. IL raised its holdings in PDS Biotechnology by 29.4% during the fourth quarter. Blair William & Co. IL now owns 157,500 shares of the company’s stock valued at $257,000 after acquiring an additional 35,757 shares during the period. Renaissance Technologies LLC raised its holdings in PDS Biotechnology by 331.0% during the fourth quarter. Renaissance Technologies LLC now owns 100,000 shares of the company’s stock valued at $163,000 after acquiring an additional 76,800 shares during the period. Finally, Marshall Wace LLP raised its holdings in PDS Biotechnology by 38.4% during the fourth quarter. Marshall Wace LLP now owns 39,024 shares of the company’s stock valued at $64,000 after acquiring an additional 10,837 shares during the period. 26.84% of the stock is owned by institutional investors.

About PDS Biotechnology

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies.